Last updated: February 21, 2026
What is NDC 00781-3004?
NDC 00781-3004 refers to Remdesivir (Veklury), an antiviral drug approved for the treatment of COVID-19. It is supplied by Gilead Sciences and has gained widespread use globally since its emergency authorization.
Market Overview
Current Market Demand
Remdesivir's demand stems primarily from hospital treatments for COVID-19. As of 2022, the global COVID-19 pandemic continues to influence sales, with the drug being a standard treatment option in many hospitals.
- Global sales (2022): Estimated at approximately $3 billion, according to IQVIA data[1].
- Key markets: United States, European Union, Japan, Canada.
- Market penetration: High in hospitals treating severe COVID-19 cases, with optional use in milder cases depending on local guidelines.
Competition Landscape
Remdesivir faces competition from other antiviral drugs, notably:
- Molnupiravir (Merck): Oral antiviral, approved in some regions for early-stage COVID-19.
- Paxlovid (Pfizer): Oral antiviral with high efficacy in early treatment.
While these options target different stages of infection, the intravenous administration route for remdesivir limits its use to in-hospital settings, impacting market share.
Regulatory and Policy Factors
- FDA (United States): Approved for hospitalized COVID-19 patients in October 2020.
- EMA (European Union): Conditional approval in mid-2021.
- CDC Guidance: Recommends remdesivir for certain hospitalized patients.
Government procurement and reimbursement policies significantly influence pricing and accessibility, especially in public health systems.
Pricing Trends and Projections
Current Pricing
- USA: List price for a 100-mg vial averages $390–$500. The typical treatment course includes six vials, totaling approximately $2,340–$3,000[2].
- European Union: Prices are lower, ranging from €200–€350 per vial, influenced by local negotiations.
Reimbursement Dynamics
- Gilead offers discounted or free vials in low-income countries.
- Public health agencies often negotiate prices, reducing the average cost.
Price Projections (2023–2027)
| Year |
Estimated Market Size (USD billions) |
Key Price Drivers |
Assumptions |
| 2023 |
$3.2 |
Continued COVID-19 variants |
Steady demand in hospitals, no significant new competing antivirals; pandemic persists. |
| 2024 |
$3.1 |
Slight demand decline |
Increased use of oral antivirals reduces IV drug demand marginally. |
| 2025 |
$2.7 |
Market saturation |
Crests as newer oral drugs gain market share; some government programs end. |
| 2026 |
$2.3 |
Equipment and hospital restrictions |
As pandemic declines, hospital utilization decreases. |
| 2027 |
$2.0 |
Shift to outpatient treatments |
Orals dominate treatment, reducing remdesivir’s market share. |
Factors influencing projections:
- Emergence of new therapies, especially oral antivirals.
- Shifts in clinical guidelines favoring outpatient treatment.
- Variability in COVID-19 infection waves affecting hospital admissions.
Future Pricing Outlook
- Pricing pressure: As demand decreases, Gilead might reduce pricing to maintain market share.
- Competing therapies: Oral antivirals may limit remdesivir's growth, leading to price stabilization or decrease.
- Biosimilar development: No current biosimilar pathways for remdesivir, limiting generic competition.
Strategic Implications
- Gilead might focus on expanding indications or developing next-generation formulations to extend market life.
- Contracting with government agencies will continue to influence drug pricing.
- Monitoring COVID-19 infection trends and treatment guidelines remains critical for accurate demand forecasting.
Key Takeaways
- The COVID-19 pandemic sustains remdesivir demand, but market growth is expected to plateau or decline from 2024 onward.
- Pricing is variable globally, heavily influenced by negotiations, subsidies, and procurement policies.
- The in-hospital administration route limits expansion compared to oral antivirals, affecting long-term market potential.
- Launch of new therapies will likely diminish remdesivir’s market share and pricing power.
- Strategic moves should include diversification of indications and formulation innovations.
FAQs
1. How does remdesivir compare to oral antivirals?
Remdesivir requires hospital administration via IV, limiting flexibility. Oral antivirals like Paxlovid and molnupiravir are easier to distribute and administer outside of hospital settings, impacting remdesivir's market share over time.
2. What are the key factors influencing remdesivir’s price?
Pricing depends on procurement negotiations, government subsidies, market demand, and the introduction of competing therapies.
3. Is remdesivir available outside high-income markets?
Yes, Gilead offers tiered pricing and donations in low-income regions to improve access, impacting the global pricing structure.
4. What potential does remdesivir have beyond COVID-19?
Research is ongoing into remdesivir’s efficacy against other viral diseases, but no significant indications have been approved.
5. How might future COVID-19 variants affect remdesivir demand?
If variants cause less severe disease or are resistant to current treatments, demand may decline, affecting future sales and pricing.
References
[1] IQVIA. (2022). Global COVID-19 drug sales report.
[2] Gilead Sciences. (2022). Remdesivir pricing and formulary information.
